INDGN2024-04-012024-06-30 INDGN2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member INDGN2024-06-30 INDGN2024-04-012024-06-30in-bse-fin:OneReportableSegmentRevenue01Member INDGN2024-04-012024-06-30in-bse-fin:OneReportableSegmentRevenue02Member INDGN2024-04-012024-06-30in-bse-fin:OneReportableSegmentRevenue03Member INDGN2024-04-012024-06-30in-bse-fin:OneReportableSegmentRevenue04Member INDGN2024-04-012024-06-30in-bse-fin:OneReportableSegmentResults01Member INDGN2024-04-012024-06-30in-bse-fin:OneReportableSegmentResults02Member INDGN2024-04-012024-06-30in-bse-fin:OneReportableSegmentResults03Member INDGN2024-04-012024-06-30in-bse-fin:OneReportableSegmentResults04Member INDGN2024-04-012024-06-30in-bse-fin:OneReportableSegmentAssets01Member INDGN2024-04-012024-06-30in-bse-fin:OneReportableSegmentAssets02Member INDGN2024-04-012024-06-30in-bse-fin:OneReportableSegmentAssets03Member INDGN2024-04-012024-06-30in-bse-fin:OneReportableSegmentAssets04Member INDGN2024-04-012024-06-30in-bse-fin:OneReportableSegmentLiabilities01Member INDGN2024-06-30in-bse-fin:OneReportableSegmentLiabilities01Member INDGN2024-04-012024-06-30in-bse-fin:OneReportableSegmentLiabilities02Member INDGN2024-06-30in-bse-fin:OneReportableSegmentLiabilities02Member INDGN2024-04-012024-06-30in-bse-fin:OneReportableSegmentLiabilities03Member INDGN2024-06-30in-bse-fin:OneReportableSegmentLiabilities03Member INDGN2024-04-012024-06-30in-bse-fin:OneReportableSegmentLiabilities04Member INDGN2024-06-30in-bse-fin:OneReportableSegmentLiabilities04Member INDGN2024-04-012024-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member INDGN2024-04-012024-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 544172 INDGN NOTLISTED Indegene Limited Equity 2024-04-01 2025-03-31 2024-08-01 2024-07-24 INR Millions First quarter 18:34:00 19:22:00 2024-08-01 2024-08-01 Not applicable Multi segment 2024-04-01 2024-06-30 Unaudited Consolidated 6765000000.00 225000000.00 6990000000.00 0.00 0.00 0.00 4443000000.00 117000000.00 201000000.00 1033000000.00 5794000000.00 1196000000.00 0.00 1196000000.00 352000000.00 -33000000.00 319000000.00 0.00 877000000.00 0.00 0.00 0.00 0.00 877000000.00 -8000000.00 869000000.00 877000000.00 0.00 869000000.00 0.00 479000000.00 2 3.79 3.76 0.00 0.00 3.79 3.76 Notes to the Statement of Consolidated Financial Results for quarter ended 30 June 2024 (All amounts in INR millions, except share data and where otherwise stated) 1. The above Consolidated Financial Results of the Group have been prepared in accordance with Indian Accounting Standards ( Ind AS ) 34 - Interim Financial Reporting, recognition and measurement principles of Indian Accounting Standards ( Ind AS ) prescribed under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. ( the regulations ). Due to rounding off, the numbers presented throughout may not add up precisely to the totals. ^ in the financial information denote amounts less than INR 0.50 million. 2. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 01 August 2024. The statutory auditors have performed an limited review of the Consolidated Financial Results for the quarter ended 30 June 2024 and have issued an unmodified review report on the same. 3. The Consolidated Financial Results include the results for the quarter ended 31 March 2024 being the balancing figure between the audited figure in respect of the full financial year and audited the year to date figure up to 31 December 2023. 4. The Consolidated Financial Results for the quarter ended 30 June 2024, are available on the National Stock Exchange of India Limited (URL: www.nseindia.com), the BSE Limited website (URL: www.bseindia.com) and on the Company's website (URL: www.indegene.com/investor-relations). 5. During the quarter ended 30 June 2024, the Company has completed Initial Public Offer (IPO) of 40,766,550 equity shares of face value of INR 2 each at an issue price of INR 452 per share, comprising fresh issue of 16,833,818 shares aggregating to INR 7,600 and offer for sale of 23,932,732 shares by selling shareholders aggregating to INR 10,818. The Equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on 13 May 2024. The Company was not mandatorily required to prepare and publish quarterly results for the quarter ended 30 June 2023 in accordance with the regulations. 6. On 22 March 2024, the Group had obtained control of Trilogy Writing & Consulting GmbH (‘Trilogy GmbH’), by acquiring 100% of its shares. The acquisition was consummated for a consideration of INR 1,457 which includes earnout payment of INR 489. The contingent consideration is based on the performance of Trilogy GmbH during the fiscal year beginning 01 April 2024 and ending 31 March 2025 and range of contingent consideration payable is between Nil to INR 1,268. The Group has concluded that the acquired set is a business. The purchase price allocation for Trilogy GmbH is provisional and will be finalized within the measurement period, but in no event later than one year following the date of acquisition. The Group is in the process of making a final determination of the fair value of assets and liabilities, contingent consideration and useful lives of certain identified intangibles. Note no. 7 and 8 are updated in Segment tab Other expenses 1033000000.00 Enterprise Commercial Solutions 3749000000.00 Enterprise Medical Solutions 1889000000.00 Omnichannel Activation 823000000.00 Others* 304000000.00 6765000000.00 6765000000.00 Enterprise Commercial Solutions 869000000.00 Enterprise Medical Solutions 441000000.00 Omnichannel Activation 88000000.00 Others* -71000000.00 1327000000.00 117000000.00 14000000.00 Financial Results Tab (Continuation) Notes to the Statement of Consolidated Financial Results for quarter ended 30 June 2024 (All amounts in INR millions, except share data and where otherwise stated) 7. Exceptional items: On 12 October 2022, the Group had obtained control of Cult Health LLC by acquiring 100% interest to enhance the Group's commercialization portfolio adding market development and brand strategy competencies along with patient engagement platforms. The acquisition was consummated for a consideration of INR 5,347. The contingent consideration is based on the performance of Cult during the fiscal year beginning 01 April 2023 and ending 31 March 2026 and range of contingent consideration payable is between INR Nil to INR 3,040. Cult Health LLC is part of Omnichannel Activation segment. The Group carried out remeasurement of the change in fair value of contingent consideration towards earnout payout, which was measured at its fair value on acquisition and recognised a resultant gain of INR 935. Change in fair value movement of contingent consideration has been recognized as an exceptional item during the quarter and year ended 31 March 2024. Further, the Group also carried out the assessment of recoverable value of the investments made in Cult Health LLC owing to reduction in revenues from certain customers and its impact on the future cash flows. The recoverable amount of this CGU estimated to be lower than carrying value, resulting into an impairment charge of INR 911. The impairment charge had been recognized as an exceptional item during the quarter and year ended 31 March 2024. 8. The Segment results of the Group has been prepared in accordance with AS-108 on Operating Segments . The Group has identified business segments (industry practice) as reportable segments. The business segments comprise: 1) Enterprise Medical Solutions, 2) Enterprise Commercial Solutions, 3) Omnichannel Activation. Notes on Segment information *Others mainly comprises of consultancy and clinical business. Operating segments are identified as components of an enterprise for which discrete financials information is available that is evaluated regularly by the chief operating decision maker. In deciding how to allocate resources and assessing performance, the Group's chief operating decision maker is the Chief Executive Officer and Executive Director. Assets and liabilities used in the Group’s business are not identified to any of the operating segments, as these are used interchangeably between segments. Management believes that it is currently not practicable to provide segment disclosures relating to total assets and liabilities since a meaningful segregation of the available data is onerous. Other unallocable expenditure net of unallocable income for the quarter ended 30 June 2024 includes depreciation and amortisation expense (INR 201) and unallocable expenses (INR 38) net of other income (INR 225). 1196000000.00 Enterprise Commercial Solutions 0.00 Enterprise Medical Solutions 0.00 Omnichannel Activation 0.00 Others* 0.00 0.00 Enterprise Commercial Solutions 0.00 Enterprise Medical Solutions 0.00 Omnichannel Activation 0.00 Others* 0.00 0.00 0.00 0.00 Remeasurement of defined benefit obligation 15000000.00 15000000.00 4000000.00 Exchange differences on translating the financial statements of foreign operations -19000000.00 -19000000.00 0.00